GENE, CELL, & RNA THERAPY LANDSCAPE REPORT Start-up funding for gene, cell, and RNA therapy · Start-up financing volume remained fairly steady from Q4 2025 to Q1 2026 with 13 seed or Series A rounds announced, just one fewer than in 2025's final quarter and aligned with the volume seen during most other recent quarters · Dollar value was down substantially in Q1 2026 to $388.4 million, a 30% decrease from Q4 2025's $557.1 million, but ahead of values from other recent quarters Copyright 0202 itelne a Norstela company.